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Centrosome amplification (CA) amongst particular breast cancer subtypes (Her2+ subtype) is associated with genomic
instability and aggressive tumor phenotypes. However, changes in signaling pathways associated with centrosome
biology have not been fully explored in subtype specific models. Novel centrosome regulatory genes that are selectively
altered in Her2+ breast cancer cells are of interest in discerning why CA is more prevalent in this subtype. To determine
centrosome/cell cycle genes that are altered in Her2+ cells that display CA (HCC1954) versus non-tumorigenic cells
(MCF10A), we carried out a gene microarray. Expression differences were validated by real-time PCR and Western blotting.
After the microarray validation, we pursued a panel of upregulated and downregulated genes based on novelty/relevance
to centrosome duplication. Functional experiments measuring CA and BrdU incorporation were completed after genetic
manipulation of targets (TTK, SGOL1, MDM2 and SFRP1). Amongst genes that were downregulated in HCC1954 cells,
knockdown of MDM2 and SFRP1 in MCF10A cells did not consistently induce CA or impaired BrdU incorporation.
Conversely, amongst upregulated genes in HCC1954 cells, knockdown of SGOL1 and TTK decreased CA in breast cancer
cells, while BrdU incorporation was only altered by SGOL1 knockdown. We also explored the Kaplan Meier Plot resource
and noted that MDM2 and SFRP1 are positively associated with relapse free survival in all breast cancer subtypes, while
TTK is negatively correlated with overall survival of Luminal A patients. Based on this functional screen, we conclude that
SGOL1 and TTK are important modulators of centrosome function in a breast cancer specific model.
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Breast cancer is the most common form of cancer detected
globally and the second leading cause of cancer-related
deaths in women. Fatality from breast cancer is mostly due
to metastasis and the risk of metastasis and relapse par-
tially correlates with tumor heterogeneity. Chromosome
instability (CIN) -defined as the active gain or loss of whole
or fragments of chromosomes during cell division- and
aneuploidy -the state of having abnormal chromosome
numbers- remain uncontested sources of genetic hetero-
geneity and are associated with the most aggressive breast
tumor types [1]. Equal segregation of chromosomes into* Correspondence: hsaaved@emory.edu
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sured by the two mitotic centrosomes that direct the
formation of a bipolar spindle [2].
Various molecular alterations, such as expression of on-
cogenes and deregulation of proteins that control the
centrosome cycle, the spindle assembly checkpoint or the
cell cycle culminate in centrosome amplification (CA), de-
fined as the presence of more than a pair of centrosomes
within a cell [2,3]. For example, we reported that a subset
of Her2+ cell lines display CA, which strongly correlated
with increased protein expression of the centrosome kinases
Nek2 and Plk4 [4]. Both of these proteins, when overex-
pressed, induced CA in mammary epithelial cells previ-
ously devoid of CA [5-7]. Emerging evidence suggests that
CIN and aneuploidy, including single chromosome losses
and polyploidy, can ensue from CA and/or cytokinesis de-
fects [2,8-10]. CA has been detected in pre-malignant le-
sions, DCIS (ductal carcinoma in situ) and in invasive. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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lates with amplification of the Her2 receptor, which affects
over 20% breast cancer patients, specifically patients dis-
playing the Her2 + ER-PR- and luminal B subtypes [11,12].
Moreover, genomically unstable and more aggressive an-
euploid breast cancers have a greater extent of CA and ab-
normal mitotic spindles compared to genomically stable
aneuploid and diploid tumors. In conclusion, preventing
the acquisition of CA, by targeting the proteins that enable
it, could potentially prevent cancer initiation and tumor
progression.
Our screening of breast cancer cell lines revealed that
CA is prevalent in a subset of Her2+ cells. Therefore, we
chose to use these cell lines as our model of breast cancer
displaying CA. We found that E2F activators, Cdk4 and
Nek2 kinases are overexpressed and/or deregulated in
these cell lines compared to non-tumorigenic mammary
epithelial cells [15,16]. Using genetic manipulation ap-
proaches, we identified that these proteins are required for
the maintenance of CA and binucleation in Her2+ breast
cancer cells. However, since these molecules regulate a
plethora of biological processes, including cell cycle pro-
gression, mitosis and cell proliferation, their potential
value as selective modifiers of CA is limited.
Here, we present data from gene array experiments per-
formed in order to identify novel centrosome and cell
cycle genes that might be selectively modified in Her2+
breast cancer cells versus non-tumorigenic cells. Our aim
was to identify differences in gene expression between
breast cancer cells with high percentages of CA and non-
transformed cells. We hypothesized that genes that are se-
lectively expressed translate into deregulated centrosome
functions and might provide therapeutic targets to spe-
cifically address CA.
We identified several molecules that might establish a
CA phenotype in Her2+ breast cancer cells. Specifically,
breast cancer cells overexpressed GINS2, TTK, CEP192,
and shugoshin 1 and have lower levels of C-Nap1, sema-
phorin 6A, MDM2 and SFRP1. Some of these proteins
have been previously linked to CA and breast cancer pro-
gression, while others have relatively unknown functions
in this context. Our findings provide relevant insight into
genetic and functional differences in centrosome regula-
tors between breast cancer and non-tumorigenic cells. Po-
tentially, selectively expressed proteins may represent
biomarkers for the identification of Her2+ tumors prone
to develop CA and other forms of genomic instability, as
well as novel therapeutic targets against CA to prevent
tumor initiation and disease progression.
Materials and methods
Cell culture
All cell lines were obtained from the ATCC or
from collaborators. Culture conditions for MCF10A,HCC1954, SKBR3 and JIMT-1 cells have been de-
scribed [17,18].
Data acquisition and processing
Total RNA was isolated using RNeasy mini kit (Qiagen)
and subjected to quality control assessment. Affymetrix
Gene Expression microarrays (Affymetrix) were used ac-
cording to the manufacturer’s protocol. Raw intensities of
the arrays (2 for MCF10A/pLKO.1 and 2 for HCC1954/
pLKO.1 cells) were normalized using quantile normalization
and then log2 transformed in the Affymetrix Human U133
platform prior to doing the analyses. Distribution of the
samples was calculated and 20% top differentially expressed
genes were selected for comparative analysis. Averaged data
were then uploaded into Metacore where gene expression
probe names were identified and differentially expressed
genes (fold threshold ≥1.5) for centrosome and cell cycle
GO processes were displayed and further analyzed.
RNA extraction and real-time PCR analysis
Two μg of RNA were used to synthesize cDNA (Promega)
following the manufacturer’s protocols. Next, two μL of
1:10 diluted cDNA were used for real-time PCR with iQ
SYBR Green supermix (170-8880, Bio-Rad). Actin was
loaded as an internal control. Primer sequences (Inte-
grated DNATechnologies) are presented in Table 1.
siRNA transfection
Cells were seeded overnight in either 60 mm culture
dishes or in four well chamber slides (Thermo Scientific).
Lipofectamine RNAiMAX (13778075, Life Technologies),
along with two hundred pmoles of each of the MDM2,
SFRP1, SGOL1 and TTK siRNA constructs (Integrated
DNA Technologies) or 5 μL of silencer negative control
siRNA #1 (50 μM) (AM4611, Life Technologies) were
transfected for 48 hours. siRNA sequences are presented
in Table 1.
Immunofluorescence for Bromodeoxyuridine (BrdU)
incorporation and centrosome amplification
BrdU staining was performed as described in our publica-
tion [8]. Briefly, forty-eight hours post transfection, BrdU
was incubated in the media of cells grown in four well
chamber slides at a final concentration of 10 μM for 30
min prior to fixing the cells in 4% paraformaldehyde for
10 min. DNA was denatured in 2 N HCl for 20 min at
room temperature, followed by neutralization in 0.1 M so-
dium borate pH 8.5 for 2 minutes. Next, cells were perme-
abilized in 0.1% NP-40 solution for 10 min after three
consecutive washes with PBS and then blocked in 10%
normal goat serum (Life Technologies) for 1 h before in-
cubation with anti-BrdU antibody (NA61, Calbiochem) at
4°C overnight. DAPI (1 mg/mL) counterstain was used.
Table 1 Primers sequences used for real-time PCR and siRNA duplexes
Primers used for real-time PCR
Genes Primer sequences
AURAK_F 5′-ATA TCT CAg Tgg Cgg ACg Ag-3′
AURAK_R 5′-TCA AAT ATC CCC gCA CTC Tgg-3′
CDC14B_F 5′-CTC CAT gAA gCg gAA AAg Cg-3′
CDC14B_F 5′-gCA AAA CAA Agg CgA TCg gT-3′
CDK1_F 5′-AAA CTg gCT gAT TTT ggC CT-3′
CDK1_R 5′-ggA gTg CCC AAA gCT CTg AA-3′
CEP192_F 5′-CCC gAg CAC TTg ATT CTg gT-3′
CEP192_R 5′-CCA CTC CAC ggg AAC ATT gA-3′
CETN2_F 5′-AgC ggA CTC CTT Tgg CTA Tg-3′
CETN2_R 5′-gCT CAg gCT TAg ggC TCA TT-3′
GINS2_F 5′-gCC gAg AAg gAg CTg gTT AC-3′
GINS2_R 5′-AAC CAg ggT TAA AAg gCC CC-3′
ROCK2_F 5′-CCC ATC AAC gTg gAg AgC TT-3′
ROCK2_R 5′-TgC CTT gTg ACg AAC CAA CT-3′
SASS6-F 5′-TAC ggA ATg AAT ggg CgT CA-3′
SASS6_R 5′-CTg TgC CTg CAA ggC TTT TT-3′
SPICE_F 5′-ggT CCC CgA gTT ggT gTA Ag-3′
SPICE_R 5′-gCg TAC CAg ATC TTC ggg Ag-3′
SGOL1_F 5′-Agg CAA AAg ATg gCC AAg gA-3′
SGOL1_R 5′-AAA gAC CTg CgT TTg CCA AT-3′
CDK14 F 5′-AAT gAg gAC ACA Tgg CCT gg-3′
CDK14_R 5′-CTg TgC CgA CAg TCT gTT CT-3′
c-Nap_F 5′-AAC CAg CTC Cgg gAg AAA Tg-3′
c-Nap_R 5′-TCT ggC ATA ggg CAC TCT CT-3′
MDM2_F 5′-CCA TgC CTg CCC ACT TTA gA-3′
MDM2_R 5′-CAg gCT gCC ATg TgA CCT AA-3′
PlexinA2_F 5′-ATT TTT CAg CCg AgA ggg Cg-3′
PlexinA2_R 5′-TTT TTC CAg CgC gAC TTT CC-3′
SEMA6A_F 5′-TgA TgC CAA ACA TgC CAA Cg-3′
SEMA6A_R 5′-gCg TCA ATg gCA Agg AAg TC-3′
SFRP1_F 5′-CTC AAC AAg AAC TgC CAC gC-3′
SFRP1_R 5′-CTC gTT gTC ACA ggg Agg AC-3′
Actin_F 5′-CgA ggC CCA gAg CAA gAg-3′
Actin_R 5′-CgT CCC AgT Tgg TAA CAA TgC-3′
TTK_F 5′-CgC AgC TTT CTg TAg AAA TggA-3′
TTK_R 5′-gAg CAT CACTTAGCGGAACAC-3′
siRNA duplexes
MDM2_1 Sense 5′-rGrGrA rCrCrU rUrGrU rArCrA rArGrA rGrCrU rUrCrA rGrGA A-3′
MDM2_1 Anti-Sense 5′-rUrUrC rCrUrG rArArG rCrUrC rUrUrG rUrArC rArArG rGrUrC rCrUrU-3′
MDM2_2 Sense 5′-rCrCrA rArGrA rCrArA rArGrA rArGrA rGrArG rUrGrU rGrGA A-3′
MDM2_2 Anti-Sense 5′-rUrUrC rCrArC rArCrU rCrUrC rUrUrC rUrUrU rGrUrC rUrUrG rGrGrU-3′
SFRP1_2 Sense 5′-rGrArA rGrCrA rArCrA rGrCrU rUrCrA rGrArA rArGrA rGrCT C-3′
SFRP1_2 Anti-Sense 5′-rGrArG rCrUrC rUrUrU rCrUrG rArArG rCrUrG rUrUrG rCrUrU rCrCrU-3′
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Table 1 Primers sequences used for real-time PCR and siRNA duplexes (Continued)
SFRP1_3 Sense 5′-rGrArA rArCrA rUrUrU rCrCrU rUrUrG rArArC rUrUrG rArUT G-3′
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BrdU + cells were calculated using fluorescent microscopy.
Centrosome amplification in transiently transfected cells
was addressed using four well slides. Forty-eight hours
post transfection, cells were fixed in 4% paraformaldehyde
for 10 min, washed in PBS, permeabilized in 0.1% NP-40
solution for 10 min and blocked in 10% normal goat serum
(Life Technologies) for 1 h, followed by overnight incu-
bation with primary antibody against pericentrin (ab4448,
Abcam). Alexa Fluor-conjugated antibodies (A11008,
A11001 or A21069, Life Technologies) were used as sec-
ondary antibodies by incubating 1 h at room temperature.
As a counter staining, DAPI (1 mg/mL) was applied. Two
hundred cells were counted and cells with ≥3 pericentrin
positive cells were presented as percentages.
Western blotting
Western blotting was performed according to our pub-
lished protocols [8,15,19]. The following primary antibodies
were used: MDM2 (sc-965, Santa Cruz Biotechnology),
SEMA6A (ab72369, Abcam), SFRP1 (ab126613, Abcam),
shugoshin 1 (ab21633, Abcam) and TTK (3255S, Cell
Signaling). Beta-actin antibody (4970, Cell Signaling) was
used as a loading control. For secondary antibodies, either
goat anti-rabbit HRP (sc-2004, Santa Cruz Biotechnology)
or goat anti-mouse HRP (sc-2005, Santa Cruz Biotechnol-
ogy) were used. Signals were detected by using a Lumigen
TMA-6 reagent (Lumigen Inc).
Statistical analysis
Student t-test was applied to compare the significances
between control and siRNA transfected counterparts. P
value ≤0.05 is considered as significant.
Results
Analysis of microarray targets
HCC1954 is a Her2+ breast cancer cell line that displays
approximately 10% CA in unsynchronized populations, sig-
nificantly higher compared to MCF10A non-transformed
cells [4,15,16]. In a parallel microarray assay (Lee andSaavedra, unpublished), we aimed to identify genes differ-
entially expressed between HCC1954 cells silenced for
E2F3 and cells expressing empty vector control (HCC1954/
pLKO.1). For that purpose, we used the lentiviral pLKO.1-
puro shRNA system to silence E2F3. The microarray ana-
lysis presented here compared the gene expression between
HCC1954 cells and MCF10A cells and was carried out in
HCC1954 cells expressing the empty lentiviral pLKO.1-
puro vector. For consistency, MCF10A/pLKO.1 non-
tumorigenic cells were used as comparison. We first se-
lected the top 20% genes that were differentially distributed
across the microarray samples and performed Metacore
gene enrichment analysis. The selected targets fell into vari-
ous categories, with genes involved in S phase regulation
and DNA damage checkpoint control being the most
highly represented (Table 2). Our initial screening ge-
nerated 2135 genes under expressed in HCC1954 versus
MCF10A cells. On the other hand, the microarray data
identified 2635 genes upregulated in HCC1954 cells rela-
tive to MCF10A. Following the analysis for centrosome
and cell cycle GO processes, we narrowed down our
findings to genes with ≥1.5 fold higher expression in
MCF10A vs HCC1954 cells and found 169 for cell cycle
and 7 for centrosome with an overlap of 3 genes be-
tween the two GOs. The downstream GO analysis indi-
cated that 421 genes with ≥1.5 higher expression in
HCC1954 cells were involved in the cell cycle, 23 were
linked to the centrosome and 21 genes pertained to
both GOs (Table 3).
Validation of microarray targets
Based on fold changes and our interests, we selected
genes that were upregulated (AURKA, CDC14B, CDK1,
CEP192, CETN2, GINS2, ROCK2, SASS6, SPICE, TTK
and SGOL1) as well as downregulated (CDK14, C-Nap1,
MDM2, PlexinA2, SEMA6A, and SFRP1) in HCC1954
cells compared to non-tumorigenic MCF10A cell line. In
addition, JIMT-1 cells, a second Her2+ cell line with
high CA [4,16], were included in this analysis to investi-
gate the similarity of molecular patterns between two
Table 2 Enrichment analysis report by process networks
Number Networks HCC1954 vs MCF10A
(P value)
Genes
1 Cell cycle, S phase 6.7436787067153E-13 RFC4, TOP2 beta, Chk2, MCM3, SG2NA, NFBD1, Brca1, Cyclin B, Cyclin B2, CRM1,
CHMP1A, ORC1L, MCM5, Nek2A, MCM4, PRIM2A, MCM10, ORC3L, DERPC, Histone
H1.5, ChAF1 subunit B, ORC6L, ASK (Dbf4), POLA1, POLE2, FEN1, DNA ligase I, p21,
RFC5, BUB1, Geminin, Sgo1, Rad51, DNA polymerase alpha/primase, PRIM1, HP1,
Securin, CDK1 (p34), C-Nap1(CEP2), Ubiquitin, PCNA, CDC18L (CDC6), Cyclin A1,
UHRF2, BRIP1, RFC3, POLD reg (p68), ATM, TOP2 alpha, POLE3-POLE4 complex, MCM6,
POLA2, GADD45 alpha, RFC1, RFC2, Cyclin A, DNA polymerase sigma, PCTK1, TOP2,
ZAK, Cdt1, Cyclin B1, POLE3 (YBL1), p53, RFC complex, Emi1, Nibrin, PKA-cat
(cAMP-dependent), Rad21, RPA2, Histone H4, DCC1, Histone H1, CDC45L
2 DNA damage checkpoint 9.94791617812864E-08 RFC4, CIA/ASF1, p38alpha (MAPK14), Chk2, 14-3-3 epsilon, NFBD1, Brca1, Cyclin B,
Cyclin B2, Cyclin D3, HUS1, CDC25C, ANAPC11, ERK1/2, Cyclin D, 14-3-3, Rad50,
CDC25A, BTG2, p21, RFC5, Securin, CDK1 (p34), ANAPC7, Cyclin D2, Ubiquitin, PCNA,
CDC23, Cyclin A1, MRE11, BRIP1, RFC3, MRN complex, FANCD2, RAD1, ATM, MDM2,
GADD45 alpha, RFC1, Ku70, RFC2, Cyclin A, Cyclin D1, JNK(MAPK8-10), NF-kB, 14-3-3
eta, p38gamma (MAPK12), RUVBL2, p53, RFC complex, Bard1, USP1, Nibrin, p38 MAPK,
Rad21
3 Cell cycle, mitosis 3.45421335237624E-07 Tubulin beta, Tubulin gamma, MIS12, HZwint-1, Cyclin B, Cyclin B2, ZW10, CAPZ beta,
Nek2A, CDC25C, Tubulin alpha 1A, CENP-A, ANAPC11, MACF1, MAD2a, CENP-H,
SPBC25, Importin (karyopherin)-alpha, Rod, RCC1, CAP-D2/D3, Kid, CDC25A, USP16,
BUB1, MPP6, Dynamin-2, Aurora-A, Actin, CDC25, CDCA1, HP1, Securin, CDK1 (p34),
SIL, ANAPC7, Ubiquitin, CDC23, PARP-2, Tubulin alpha, Dynein 1, cytoplasmic, heavy
chain, Tctex-1, Survivin, Karyopherin alpha 2, MAPRE3(EB3), Dynamin-3, ANAPC10,
DLC1 (Dynein LC8a), BUBR1, CAP-H/H2, NF45 (ILF2), Cyclin A, EML4, HEC, TTK, CAS-L,
TOP2, MAD2L1BP, 14-3-3 eta, Dynamin, MCAK, Cyclin B1, PAFAH alpha (LIS1), RAE1,
PARD6, HP1 gamma, Rad21, Zwilch, NSL1, Histone H1, Tubulin (in microtubules)
4 Cell cycle, G2-M 8.54322861724783E-07 TOP2 beta, p38alpha (MAPK14), Chk2, TCP1-theta, 14-3-3 epsilon, EGF, TCP1-delta,
NFBD1, Brca1, Cyclin B, Cyclin B2, GRB2, HUS1, Nek2A, CDC25C, HIPK2, p38delta
(MAPK13), EGFR, ANAPC11, NEDD8, MAD2a, ERK1/2, 14-3-3, Histone H1.5, Centrin-2,
RCC1, Rad50, CAP-D2/D3, Kid, CDC25A, p21, BUB1, Rad51, CDK10, Aurora-A, CDC25,
p90Rsk, Securin, CDK1 (p34), RINT-1, ANAPC7, Ubiquitin, FHIT, CDC23, Cyclin A1, Shc,
CKS1, TRF1, FANCD2, ATM, AKT3, MRLC, Lamin B1, TCP1-epsilon, BUBR1, TOP2 alpha,
CAP-H/H2, LATS2, Lamin B, IGF-1 receptor, GADD45 alpha, Cyclin A, CNAP1, PCTK1,
TOP2, AKT(PKB), ZAK, 14-3-3 eta, Dynamin, BRRN1, p38gamma (MAPK12), Cyclin B1,
p53, Emi1, p38 MAPK, PKA-cat (cAMP-dependent), MAT1, Histone H1
5 DNA damage, BER-NER
repair
1.15885388728944E-06 RFC4, Chk2, OGG1, NEIL3, NFBD1, Brca1, PARP-1, HUS1, MBD4, NEIL1, ERCC6, Rad50,
DNA polymerase beta, POLE2, XPF, FEN1, DNA ligase I, RFC5, TFIIH p52 subunit, TDG,
TFIIH p34 subunit, PCNA, UNG1, PARP-2, MRE11, DDB2, RFC3, RAD23B, MRN complex,
RAD1, POLD reg (p68), ATM, PARG, POLE3-POLE4 complex, RFC1, RFC2, Brca1/Bard1,
PARP-3, POLE3 (YBL1), p53, RFC complex, Bard1, Nibrin, MBD1, XPD, RPA2, MAT1, TFB5
6 Cell adhesion, cell
junctions
7.60204508182795E-06 Tubulin beta, Tiam1, VE-cadherin, BPAG2, N-cadherin, E-cadherin, ITGB1, 14-3-3
epsilon, Cingulin, MUPP1, Tcf(Lef), ZO-1, Fer, ERK1/2, Keratin 5, 14-3-3, Claudin-16,
Beta-catenin, Nectin-2, BPAG1, DLG5(P-dlg), Connexin 46, Claudin-8, Desmoglein 3,
Vimentin, Actin, Paxillin, MAGI-1(BAIAP1), GIT1, PI3K reg class IA (p85), JAM3, ATP1B1,
Tubulin alpha, Desmocollin 3, R-cadherin, PKC, PLC-beta, Endothelin-1, CASK, Keratin
18, Desmoglein 2, Beta-fodrin, Claudin-7, Itch, PLC-gamma, Keratin 8/18, Claudin-4,
SIP1 (ZFHX1B), Nectin-3, Desmoplakin, Keratin 8, ZO-3, PSD-95, Keratin 6A, PEZ, ERK2
(MAPK1), Caveolin-1, 14-3-3 eta, Claudin-3, PARD6, Connexin 31, Tubulin (in microtubules)
7 Cell cycle, core 0.000013064502255225 MCM3, p14ARF, Cyclin B, Cyclin B2, Cyclin D3, ZW10, ORC1L, MCM5, Nek2A, CDC25C,
CENP-A, MCM4, MCM10, ORC3L, MAD2a, CENP-H, Cyclin D, Rod, Kid, CDC25A, ORC6L,
ASK (Dbf4), FEN1, DNA ligase I, p21, BUB1, DNA polymerase alpha/primase, Aurora-A,
Securin, CDK1 (p34), Cyclin E2, CDC18L (CDC6), Survivin, BUBR1, MCM6, Cyclin A,
Cyclin D1, HEC, TOP2, Cdt1, Cyclin B1, p16INK4, Emi1, RPA2, Zwilch, MAT1, CDC45L
8 Cell adhesion, cadherins 0.0000405298162912831 RACK1, WNT4, VE-cadherin, BPAG2, N-cadherin, E-cadherin, ITGB1, PCDHA6, PCDHA4,
VLDLR, Tcf(Lef), EGFR, Ski, ZO-1, Presenilin 1, Fer, DKK1, PCDHGC3, Casein kinase I
epsilon, Beta-catenin, Nectin-2, H-cadherin, PTPR-mu, SSX2IP, BPAG1, DLG5(P-dlg),
PCDHGB2, Desmoglein 3, Actin, CTNNAL1, Protocadherin 18, PCDHGA3, Shc, PI3K reg
class IA (p85), PCDA7, Desmocollin 3, R-cadherin, MTSS1, Cadherin 10, FAT1, PKC,
PCDHGA1, FHL2, PKC-alpha, Protocadherin gamma B1, Desmoglein 2, WNT, WNT10B,
EVL, Nectin-3, LRP6, Axin2, Casein kinase I, PCDHGA12, Fyn, Vinexin, DAB1, PEZ, AKT
(PKB), PDZK3, PCDHGB4, Axin, PTPR-zeta, Frizzled, Tubulin (in microtubules)
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Table 2 Enrichment analysis report by process networks (Continued)
9 Proteolysis ubiquitin-
proteasomal proteolysis
0.0000769830526795964 MDM4, HAUS7, Brca1, PSMB8(LMP7), KEAP1, PSMA4, Cullin 2, c-Cbl, UBCH7, UCHL3,
SAE1/2, TGT, PSMB1, PSMC3, PSMC6, PSMD5, PSMA7, PSMC4, SENP2, SAE1, GRAIL,
PSMD10 (Gankyrin), PSME1, DTX3, Ubiquitin, PSMD3, PSMD2, RAD23B, NF-X1, PSMB6,
MUF1, PSME2, PSMD8, PSMD7, Syntaxin 5, Itch, Elongin C, MPDZ, NEDD4L, MDM2,
DORFIN, PSMB3, UBC7, PSMD14, Brca1/Bard1, RING-box protein 1, PSMB7, PSMD12,




0.00008172060696576 Tubulin beta, Tubulin gamma, KIF4A, HZwint-1, Cyclin B, HOOK1, Cyclin B2, ZW10,
Nek2A, Tubulin alpha 1A, CENP-A, Tubulin delta, MAD2a, CENP-H, Importin
(karyopherin)-alpha, Rod, RCC1, MKLP2, Kid, BUB1, Sororin, Aurora-A, Securin, CDK1
(p34), ANAPC7, Tubulin alpha, Dynein 1, cytoplasmic, heavy chain, Karyopherin alpha
2, 4.1N, DLC1 (Dynein LC8a), BUBR1, DORFIN, DEEPEST, MID1, EML4, HEC, TTK, MCAK,
Cyclin B1, PAFAH alpha (LIS1), RAE1, Zwilch, Tubulin (in microtubules)
Table 3 Deregulated centrosome genes
Gene symbol Gene name HCC1954/MCF10A
PLK2 polo-like kinase 2 5.82
SGOL1 shugoshin-like 1 (S. pombe) 4.24
CETN2 centrin, EF-hand protein, 2 4.12
AURKA aurora kinase A 4.01
BRCA1 breast cancer 1, early onset 3.77
CDK1 cyclin-dependent kinase 1 3.50
SON SON DNA binding protein 3.09
NEK2 NIMA (never in mitosis gene a)-related kinase 2 2.89
RANBP1 RAN binding protein 1 2.82
CEP76 centrosomal protein 76 kDa 2.46
GADD45A growth arrest and DNA-damage-inducible, alpha 2.40
TMEM67 transmembrane protein 67 2.40
TBCCD1 TBCC domain containing 1 2.36
SASS6 spindle assembly 6 homolog (C. elegans) 2.33
UXT ubiquitously-expressed, prefoldin-like chaperone 2.27
XPO1 exportin 1 (CRM1 homolog, yeast) 2.13
HAUS2 HAUS augmin-like complex, subunit 2 2.13
CEP192 centrosomal protein 192 kDa 2.03
HAUS7 HAUS augmin-like complex, subunit 7 2.03
SPICE1 spindle and centriole associated protein 1 2.01
CTNNB1 catenin (cadherin-associated protein), beta 1, 88 kDa 1.88
HAUS5 HAUS augmin-like complex, subunit 5 1.65
PAFAH1B1 platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 (45 kDa) 1.50
NDEL1 nudE nuclear distribution E homolog (A. nidulans)-like 1 −1.50
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 −1.76
PKD2 polycystic kidney disease 2 (autosomal dominant) −1.80
PCM1 pericentriolar material 1 −1.82
CEP250 centrosomal protein 250 kDa −1.89
PLXNA2 plexin A2 −3.92
SEMA6A sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A −6.99
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http://www.celldiv.com/content/9/1/3different Her2+ cell lines (Table 4). Semi-quantitative PCR
analysis validated the differential expression for most genes
downregulated in HCC1954 cells (Figure 1A) and for some
genes upregulated in this cell line (Figure 1C). Consistent
with this finding, similar trends were found by real-time
PCR analysis (Figure 1B,D). The results show that, com-
pared to MCF10A control, MDM2 and PlexinA2 were
significantly downregulated in JIMT-1 and in HCC1954
cells. On the other hand, C-Nap1 and SFRP1 RNA levels
were significantly increased in JIMT-1 cells compared to
MCF10A cells. Among the upregulated genes in HCC1954
cells, AURKA, CETN2 and GINS2 RNA levels were sig-
nificantly increased compared to MCF10A and all of the
genes investigated, with the exception of SAS6 and SPICE,
were more highly upregulated in JIMT-1 cells than in
HCC1954 cells. These data validated our microarray ana-
lysis and confirmed differences of molecular signatures be-
tween two Her2+ breast cancer cell lines.
Transient knockdown of SEMA6A or MDM2 and
centrosome amplification in MCF10A cells
After the real-time PCR validation of the microarray targets,
we chose to further pursue three genes; MDM2, SEMA6A
and SFRP1 that were downregulated in HCC1954 cells,
based on the relevance and novelty of their function in
centrosome duplication. First, we investigated protein ex-
pression by Western blot (Figure 2A). Both SEMA6A and
SFRP1 protein levels were highly decreased in three Her2+
cell lines, HCC1954, JIMT-1 and SKBR3 compared to non-
transformed normal epithelial MCF10A cells. However,Table 4 Differential expression of selected cell cycle and cent

















[GenBank:NM_001012410] SGOL1unlike real-time PCR data, MDM2 protein levels across the
three Her2+ cell lines were comparable to those of MCF10A
cells. Since two of these proteins were less abundant in
breast cancer cells, we speculated that at high levels, these
molecules would represent suppressors of CA. To test this
possibility, we proceeded to knock these genes down in
MCF10A cells using siRNAs to test whether their downreg-
ulation induces CA. As illustrated in Figure 2B, we were
able to effectively knockdown both MDM2 and SFRP1 with
two independent sequences targeting different regions of
the genes. However, we did not achieve knockdown of
SEMA6A using the same strategy; thus, we eliminated this
gene from further experiments. Even though both siRNA
sequences significantly decreased MDM2 and SFRP1 pro-
tein levels in MCF10A cells, only one duplex for each gene
(MDM2_1, SFRP1_3) induced CA (Figure 2). Similar results
were obtained for the BrdU incorporation assay, since only
one sequence (MDM2_1, SFRP1_2, respectively) decreased
the extent of BrdU incorporation.
Transient knockdown of SGOL1 or TTK decreases
centrosome amplification in Her2+ cells
From the subset of genes that were upregulated in
HCC1954 cells compared to MCF10A cells, we chose
shugoshin 1 (SGOL1) and TTK, based on their relevance
and novelty, since the centrosome roles of these genes
are not fully understood, especially in cancer models.
We predicted that their gene products are required for
CA and proceeded to silence them in order to address
whether their silencing would diminish percentages ofrosome genes
lls Metacore fold change Fold changes, real-time PCR
HCC1954 JIMT-1
14.26 0.53 ± 0.48 1.19 ± 0.23
1.89 0.90 ± 0.18 3.13 ± 0.27
3.18 0.04 ± 0.01 0.28 ± 0.13
3.92 0.37 ± 0.07 0.04 ± 0.01
6.99 0.01 ± 0.01 0.04 ± 0.01
38.04 0.00 ± 0.00 1.96 ± 0.07
ls
4.62 2.10 ± 1.11 N/A
4.01 5.14 ± 0.91 3.2 ± 0.46
3.5 1.06 ± 0.37 2.85 ± 0.65
2.03 2.03 ± 0.81 4.36 ± 0.55
4.12 2.42 ± 0.30 4.77 ± 1.27
11.49 4.76 ± 1.59 1.41 ± 0.04
<1.5 1.46 ± 0.61 4.41 ± 0.70
2.33 1.33 ± 0.36 2.13 ± 0.41
2.01 2.50 ± 0.87 2.45 ± 1.11















































































































































































































Figure 1 Differential expression of cell cycle regulators and centrosomal genes between MCF10A cells and Her2+ breast cancer cells.
Semi-quantitative PCR (A) and real time PCR analysis (B) of genes downregulated in Her2+ breast cancer cells compared to MCF10A cells.
Semi-quantitative PCR (C) and real time PCR analysis (D) of genes upregulated in Her2+ breast cancer cells compared to MCF10A cells.
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http://www.celldiv.com/content/9/1/3CA in Her2+ breast cancer cells. Western blot analysis
shown in Figure 3A confirmed that protein levels of
SGOL1 and TTK were much higher in unsynchronized
populations of Her2+ cell lines compared to MCF10A
cells. Next, we transiently knocked down both proteins
by using at least two independent siRNA duplexes,
achieving total silencing with SGOL1_1 and partial
downregulation with SGOL1_2 (Figure 3B). Knockdown
of SGOL1 with SGOL1_1 decreased the percentages of
CA in both HCC1954 and JIMT-1 cell lines compared
to scrambled negative control and the same clone
reduced percentages of BrdU + cells in JIMT-1 cells
(Figure 3C,D). Knockdown of TTK with two independ-
ent siRNA sequences reduced the percentages of CA in
HCC1954 cells (Figure 3C) and modestly affected BrdU
incorporation (Figure 3D). These data suggest that re-
duced CA detected in HCC1954 and JIMT-1 cells by
transient knockdown of SGOL1 may derive from thereduced DNA replication. However, the reduction in
CA observed after transient knockdown of TTK is due
to a mechanism apart from changes in DNA replication.
Association of MDM2, SFRP1, and TTK expression with
the outcome of breast cancer patients
To explore the clinical relevance of the target genes, we
used the http://kmplot.com/analysis/ resource that pro-
vides an online survival analysis tool to rapidly assess the
effect of 22,277 genes on breast cancer prognosis using
microarray data of 1809 patients [20]. We found that
MDM2 and SFRP1 transcripts were positively correlated
with relapse free survival for all breast cancer subtypes
and the results were statistically significant (Figure 4A,B).
In the case of TTK, RNA level was negatively correlated
with overall survival of luminal A breast cancer patients,
showing statistical significance (Figure 4C). However, no


































































































Figure 2 MDM2 and SFRP1 in centrosome amplification. (A) Basal levels of MDM2, semaphorin 6A and SFRP1 are higher in unsynchronized
populations of MCF10A cells compared to Her2+ breast cancer cell lines. (B) MCF10A cells were transfected with siRNA duplexes against MDM2
or SFRP1. Western blots indicate the transient knockdown of MDM2 and SFRP1. Quantifications of centrosome amplification by pericentrin
immunofluorescence (C) and of BrdU incorporation by fluorescence microscopy (D).
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Centrosome amplification (CA) is a precursor of chromo-
some instability and polyploidy and may facilitate the ac-
quisition and maintenance of several malignant phenotypes
in breast tumors. Previously, we screened breast cancer cell
lines of various subtypes to find an accurate model for CA
studies and found three Her2+ cell lines; HCC1954, JIMT-
1 and SKBR3 that displayed significant CA compared to
MCF10A non-tumorigenic epithelial cells [4,16]. To seek
out new targets differentially expressed in these cell lines,
thereby potentially modulating the extent of CA, we per-
formed a microarray based on Affymetrix platform using
MCF10A cells and HCC1954 cells as a starting point and
explored several selected targets by real time PCR and
Western blots.
Amongst the differentially expressed genes, we identi-
fied downregulation of secreted frizzled-related protein-
1 (SFRP-1) in three Her2+ breast cancer cell lines. SFRPs
are inhibitory WNT family members that block the
WNT signaling pathway and the competition betweenFrizzled and SFRP1 for binding to WNT regulates the
pathway activation [21]. There is a plethora of evidence of
loss of SFRP1 expression in many cancers including breast
cancer [22-25], suggesting that this gene acts as a mam-
mary tumor suppressor. SFRP1 is expressed in the normal
breast epithelium and its expression is lost in more than
80% of invasive breast carcinomas [26]. In a mouse model,
10 week old nulliparous SFRP1-/- animals showed in-
appropriate mammary gland development relative to
controls, evidenced by extensive branching with clear
lobulo-alveolar development, along with a significantly
higher density of ducts with distinct alveoli present
throughout the mammary gland [27]. More recently,
Matsuda et al showed that ectopic expression of SFRP1 in
MDA-MB-231 triple negative breast cancer cells blocks
canonical WNT signaling and decreases their migration
potential and cell proliferation in a xenograft model along
with dramatically impairing lung metastases [28]. Another
relevant study showed that triple negative breast can-





























































































































































































Figure 3 Shugoshin 1 and TTK maintain centrosome amplification in Her2+ breast cancer cells. (A) Basal levels of SGOL1 and TTK are
higher in unsynchronized populations of Her2+ breast cancer cell lines compared to MCF10A cells. JIMT-1 cells were transfected with siRNA
duplexes against SGOL1 and HCC1954 cells were transfected with siRNA against SGOL1 or TTK. (B) Western blots indicating the transient
knockdown of SGOL1 in JIMT-1 and HCC1954 cells (left) and TTK in HCC1954 cells (right). Quantifications of fluorescent microscopy for
centrosome amplification by pericentrin staining (C) and of BrdU incorporation (D).
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http://www.celldiv.com/content/9/1/3methyltransferase inhibitor decitabine induced reexpres-
sion of SFRP1, along with synergistic inhibition of cell
growth and induction of apoptosis [29]. To date, there
have been no reports about the function of SFRP1 in
regards to CA. In this study, we show that in normal epi-
thelial MCF10A cells, SFRP1 knockdown with siRNA se-
quences did not consistently induce CA.
MDM2, mouse double minute 2 homolog, first identi-
fied as an inhibitor of p53 transcriptional activation [30],
is an E3 ubiquitin ligase that targets p53 degradation,thereby keeping p53 levels and activity low in unstressed
cells [31]. The molecular significance of MDM2 stems
from its ability to interact with more than 100 molecules
[32]. For instance, activation of E2F1 is stimulated by its
binding to MDM2 [33]. Amplification or altered expres-
sion of MDM protein has been found in many tumors
[34-36]. In terms of its breast cancer-promoting proper-
ties, Smad3/4 transcription factors activated by TGF-β1
bind to the promoter region of MDM2 to increase its pro-





Figure 4 Correlations between the levels of MDM2, SFRP1 or TTK and survival of breast cancer patients. (A) Kaplan-Meier curve for
MDM2 expression and relapse-free survival of breast cancer patients of all subtypes. (B) Kaplan-Meier curve for SFRP1 expression and relapse-free
survival of breast cancer patients of all subtypes. (C) Kaplan-Meier curve for TTK expression and overall survival of luminal A breast cancer patients.
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the epithelial to mesenchymal transition and are able to
migrate. Also, MDM2 overexpression in MCF-7 (estrogen
receptor positive, Her2-negative) and MDA-MB-231
(triple-negative) cell lines promotes invasion and metasta-
sis in invasive ductal breast carcinoma by upregulating
matrix metalloproteinase-9 [38]. There have been a hand-
ful of reports about overexpression of MDM2 and CA,
but never one that addresses the effects of its downregu-
lation and CA. For example MDM2 overexpression pro-
motes CA in tumors that retain wild-type p53 [39].
However, later studies showed that the functions of
MDM2 in inducing genomic instability and transform-
ation could also be p53-independent [40-43]. Our vali-
dated microarray revealed highly decreased mRNA levels
of MDM2 in Her2+ cells compared to MCF10A but
MDM2 protein level was not diminished. Similar to
SFRP1, knockdown of MDM2 with siRNA did not con-
sistently induce CA. In this report, we found that lower
MDM2 mRNA expression negatively correlates with
disease-free survival. In summary, the mechanisms re-
sponsible for the acquisition of SFRP1 or MDM2-
mediated CA need to be further investigated and oneinteresting aspect is whether SFRP1 or MDM2 overex-
pression in Her2+ cells decreases CA.
From the 2635 genes overexpressed in HCC1954 Her2+
breast cancer cells versus non-tumorigenic control and
following downstream analyses, shugoshin 1 and TTK
piqued our interest. These genes are of interest due to po-
tential diverse functions associated with chromosome seg-
regation, spindle formation and centrosome cycle. The
impact of these genes on CA is also unclear and contro-
versial. We did not study Aurora A kinase, the top centro-
some upregulated gene, since Aurora A overexpression is
known to promote CA [44,45]. Likewise, Nek2 is another
kinase we did not address, since our previous publications
indicate it maintains CA and CIN in Her2+ breast cancer
cells [15,16] and in MCF10A cells expressing H-RasG12V
or H-RasG12V and c-Myc [46]. Shugoshin proteins (SGOL1
and SGOL2) prevent the cleavage of cohesion complexes
localized around sister chromatids by separase from S
phase to metaphase. In vertebrates, this function is prob-
ably achieved via the interaction between SGOL1 and the
PP2A phosphatases that counteract the phosphorylation
of cohesion subunits [47,48]. SGOL1 interacts with the
spindle assembly checkpoint (SAC) kinase Bub1 and this
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shugoshin [49-52]. Centromeric localization of SGOL1 is
also promoted by the interaction with Aurora B kinase of
the chromosomal passenger complex (CPC) [52]. Finally,
because of phosphorylation by Nek2, SGOL1 integrates
the centromeric cohesion and spindle attachment at the
kinetochore [53]. Although not very abundant, the current
literature clearly points out that shugoshin can accomplish
multiple functions, such as chromatid and centriole co-
hesion or spindle assembly. Therefore, SGOL1 is crucial
for chromosome segregation and mitotic progression
and its deregulation can have detrimental effects includ-
ing centrosome amplification, chromosome instability,
and aneuploidy. Depletion of SGOL1 precludes viability
as demonstrated by Sgol 1 knockout mouse studies [50].
Overexpression of SGOL1 was detected in the sera of
breast cancer patients [54] and has been associated with
additional human cancers, including gastric, colorectal,
AML and NSCLC [48,55-57]. In stark contrast with
these clinical correlations, another study in colorectal
cancer found low levels of SGOL1 in tumor samples
while in cell culture SGOL1 knockdown induced CA,
CIN and mitotic catastrophe [58]. A genome-wide RNAi
array performed in oral squamous cancer cells detected
SGOL1 as one of the molecules implicated in centrosome
clustering [59]. This is a phenomenon that typically occurs
in cells with amplified centrosomes and leads to the for-
mation of pseudopolar spindles and bipolar division, as
opposed to mitotic multipolar spindles that cause cell
death [10]. Various functional assays demonstrated that
transient silencing of SGOL1 resulted in mitotic arrest,
multipolar spindles, reduced spindle tension, and cell
death [59]. This seminal work showing that depletion of
SGOL1 inhibits centrosome clustering is consistent with
our data confirming a linear correlation between the ex-
tent of SGOL1 knockdown and the decrease of centro-
some amplification, as measured by pericentrin labeling,
and also a correlation with decreased DNA synthesis. Our
findings presented here represent the first evidence of the
biological relevance of SGOL1 in a breast cancer cell
model and the first indication that its overexpression pro-
motes CA. In conclusion, the versatile SGOL1 protein
may coordinate critical interactions involving the spindles
and chromosome biology. As a result, deregulated SGOL1
localization and function in breast cancer cells can signi-
ficantly contribute to the acquisition of CA, centrosome
clustering, chromosome missegregation and instability
and aneuploidy. Based on this evidence, SGOL1 is an at-
tractive target for blocking the progression of genomically
unstable breast tumors that display CA. However, the mo-
lecular biology underlying the centrosome and centromere
functions of SGOL1 awaits more studies.
TTK, also known as monopolar spindle 1, is a dual
specificity kinase with well characterized roles in thespindle assembly checkpoint [60]. In addition to its func-
tion during mitosis, TTK has also shown a role in centri-
ole duplication and assembly [61,62]. Proper levels and
regulation of TTK are partially responsible for ensuring
accurate centriole duplication and assembly during the
cell cycle [63]. One mechanism which prevents TTK ac-
cumulation from resulting centriole re-duplication is
through control of TTK levels via the MPS1 degradation
signal [62]. Although TTK may not be required for nor-
mal centriole duplication, several studies support the
notion that overexpressed TTK results in centriole re-
duplication, which could lead to CA. In breast cancer,
increased TTK mRNA levels have been noted across
many cell lines, specifically Her2+ and triple negative
subtypes and in tumor samples collected from patients
with advanced disease [64-66]. These correlations suggest
an association between TTK levels and cancer behavior
(i.e. cell proliferation, tumor aggressiveness). Thus, TTK
presents a potential biomarker to predict patient prognosis
in breast cancer or as a useful drug target for a subset of
breast cancers. Previous studies have revealed how modi-
fying TTK expression levels affects cell viability, mitosis
and tumor growth in vivo but none have addressed TTK’s
functional roles involved with CA in breast cancer [64,65].
In this report, we show for the first time that attenuating
TTK levels can decrease the percentages of CA observed
in a subset of Her2+ breast cancer cells without affecting
the integrity of DNA synthesis. Further dissection of the
mechanism for how TTK can drive CA and genomic in-
stability in specific breast cancer subtypes will be a key to
understanding the correlations between high TTK levels
and more aggressive/drug resistant breast tumors.
Abbreviations
CA: Centrosome amplification; CIN: Chromosome instability; ER: Estrogen
receptor; PR: Progesterone receptor; DCIS: Ductal carcinoma in situ;
MDM2: Mouse double minute 2 homolog; SFRP1: Secreted frizzled-related
protein 1; SGOL1: Shugoshin-like 1; BrdU: 5-bromo-2-deoxyuridine; DAPI:
4′,6-diamidino-2-phenylindole; GO: Gene ontology; AML: Acute myeloid
leukemia; NSCLC: Non-small cell lung cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
ML: Performed semi-quantitative and real-time PCR, siRNA knockdown of
SFRP1 and MDM2, CA and BrdU assays and wrote part of manuscript. MM:
Analyzed normalized microarray data, performed GO analysis, siRNA
knockdown of SGOL1, CA and BrdU assays and wrote part of manuscript.
JLK: Performed TTK real-time PCR, siRNA knockdown of TTK, CA and BrdU
assays and wrote part of the manuscript. HIS: Designed the project and
edited the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Khanjan Gandhi and Dr. Jeanne Kowalski from the
Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute for
the assistance with the microarray data acquisition and normalization.
Research reported in this publication was supported by the Integrated
Cellular Imaging (ICI) Shared Resource of Winship Cancer Institute of Emory
University and NIH/NCI under award number P30CA138292 and by R01
CA151521 from the National Institutes of Health. The content is solely the
Lee et al. Cell Division 2014, 9:3 Page 13 of 14
http://www.celldiv.com/content/9/1/3responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health.
Author details
1Department of Radiation Oncology, Winship Cancer Institute, Emory
University School of Medicine, C3084, 1365C Clifton Road NE, Atlanta, GA
30322, USA. 2Cancer Biology Graduate Program, Emory University School of
Medicine, 1365C Clifton Road NE, Atlanta, GA 30322, USA.
Received: 29 July 2014 Accepted: 8 September 2014
Published: 25 September 2014
References
1. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I,
Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J,
Kschischo M, Szallasi Z, Swanton C: Relationship of extreme chromosomal
instability with long-term survival in a retrospective analysis of primary
breast cancer. Cancer Epidemiol Biomarkers Prev 2011, 20:2183–2194.
2. Fukasawa K: Oncogenes and tumour suppressors take on centrosomes.
Nat Rev Cancer 2007, 7:911–924.
3. Harrison MK, Adon AM, Saavedra HI: The G1 phase Cdks regulate the
centrosome cycle and mediate oncogene-dependent centrosome ampli-
fication. Cell Div 2011, 6:2.
4. Marina M, Saavedra HI: Nek2 and Plk4: prognostic markers, drivers of
breast tumorigenesis and drug resistance. Front Biosci (Landmark Ed) 2014,
19:352–365.
5. Wang S, Li W, Liu N, Zhang F, Liu H, Liu F, Liu J, Zhang T, Niu Y: Nek2A
contributes to tumorigenic growth and possibly functions as potential
therapeutic target for human breast cancer. J Cell Biochem 2012,
113:1904–1914.
6. Lee J, Gollahon L: Mitotic perturbations induced by Nek2 overexpression
require interaction with TRF1 in breast cancer cells. Cell Cycle 2013,
12:3599–3614.
7. Godinho SA, Picone R, Burute M, Dagher R, Su Y, Leung CT, Polyak K,
Brugge JS, Thery M, Pellman D: Oncogene-like induction of cellular
invasion from centrosome amplification. Nature 2014, 510:167–171.
8. Adon AM, Zeng X, Harrison MK, Sannem S, Kiyokawa H, Kaldis P, Saavedra
HI: Cdk2 and Cdk4 regulate the centrosome cycle and are critical
mediators of centrosome amplification in p53-null cells. Mol Cell Biol
2010, 30:694–710.
9. Tarapore P, Horn HF, Tokuyama Y, Fukasawa K: Direct regulation of the
centrosome duplication cycle by the p53-p21Waf1/Cip1 pathway.
Oncogene 2001, 20:3173–3184.
10. Godinho SA, Kwon M, Pellman D: Centrosomes and cancer: how cancer
cells divide with too many centrosomes. Cancer Metastasis Rev 2009,
28:85–98.
11. Guo HQ, Gao M, Ma J, Xiao T, Zhao LL, Gao Y, Pan QJ: Analysis of the
cellular centrosome in fine-needle aspirations of the breast. Breast Cancer
Res 2007, 9:R48.
12. Schneeweiss A, Sinn HP, Ehemann V, Khbeis T, Neben K, Krause U, Ho AD,
Bastert G, Kramer A: Centrosomal aberrations in primary invasive breast
cancer are associated with nodal status and hormone receptor
expression. Int J Cancer 2003, 107:346–352.
13. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL: Centrosome
hypertrophy in human breast tumors: implications for genomic stability
and cell polarity. Proc Natl Acad Sci U S A 1998, 95:2950–2955.
14. Lingle WL, Salisbury JL: Altered centrosome structure is associated with
abnormal mitoses in human breast tumors. Am J Pathol 1999,
155:1941–1951.
15. Harrison Pitner MK, Saavedra HI: Cdk4 and nek2 signal binucleation and
centrosome amplification in a her2+ breast cancer model. PLoS One
2013, 8:e65971.
16. Lee MY, Moreno CS, Saavedra HI: The E2F activators signal and maintain
centrosome amplification in breast cancer cells. Mol Cell Biol 2014,. May 5.
[Epub ahead of print].
17. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N,
Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ,
Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F,
Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW: A
collection of breast cancer cell lines for the study of functionally distinct
cancer subtypes. Cancer Cell 2006, 10:515–527.18. Eddy SF, Kane SE, Sonenshein GE: Trastuzumab-resistant HER2-driven
breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Res
2007, 67:9018–9023.
19. Hagen KR, Zeng X, Lee MY, Tucker Kahn S, Harrison Pitner MK, Zaky SS, Liu
Y, O’Regan RM, Deng X, Saavedra HI: Silencing CDK4 radiosensitizes breast
cancer cells by promoting apoptosi. Cell Div 2013, 8:8.
20. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An
online survival analysis tool to rapidly assess the effect of 22,277 genes
on breast cancer prognosis using microarray data of 1,809 patients.
Breast Cancer Res Treat 2010, 123:725–731.
21. Zorn AM: Cell-cell signalling: frog frizbees. Curr Biol 1997, 7:R501–504.
22. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B,
Birnbaum D, Pebusque MJ: Differential expression assay of chromosome
arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast
Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes.
Oncogene 1999, 18:1903–1910.
23. Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B, Galm O,
Camara O, Durst M, Kristiansen G, Huszka C, Knüchel R, Dahl E: Aberrant
methylation of the Wnt antagonist SFRP1 in breast cancer is associated
with unfavourable prognosis. Oncogene 2006, 25:3479–3488.
24. Klopocki E, Kristiansen G, Wild PJ, Klaman I, Castanos-Velez E, Singer G, Stohr
R, Simon R, Sauter G, Leibiger H, Essers L, Weber B, Hermann K, Rosenthal A,
Hartmann A, Dahl E: Loss of SFRP1 is associated with breast cancer
progression and poor prognosis in early stage tumors. Int J Oncol 2004,
25:641–649.
25. Wong SC, Lo SF, Lee KC, Yam JW, Chan JK, Wendy Hsiao WL: Expression of
frizzled-related protein and Wnt-signalling molecules in invasive human
breast tumours. J Pathol 2002, 196:145–153.
26. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F,
Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ: WNT
pathway and mammary carcinogenesis: loss of expression of candidate
tumor suppressor gene SFRP1 in most invasive carcinomas except of the
medullary type. Oncogene 2001, 20:5810–5817.
27. Gauger KJ, Shimono A, Crisi GM, Schneider SS: Loss of SFRP1 promotes ductal
branching in the murine mammary gland. BMC Dev Biol 2012, 12:25.
28. Matsuda Y, Ichida T: Impact of hepatitis B virus X protein on the DNA
damage response during hepatocarcinogenesis. Med Mol Morphol 2009,
42:138–142.
29. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME,
Tun HW, Colon-Otero G, Perez EA, Copland JA: Reexpression of tumor
suppressor, sFRP1, leads to antitumor synergy of combined HDAC and
methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther
2012, 11:2105–2115.
30. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2
oncogene product forms a complex with the p53 protein and inhibits
p53-mediated transactivation. Cell 1992, 69:1237–1245.
31. Wade M, Li YC, Wahl GM: MDM2, MDMX and p53 in oncogenesis and
cancer therapy. Nat Rev Cancer 2013, 13:83–96.
32. Fahraeus R, Olivares-Illana V: MDM2′s social network. Oncogene 2014,
33:4365–4376.
33. Martin K, Trouche D, Hagemeier C, Kouzarides T: Regulation of
transcription by E2F1/DP1. J Cell Sci Suppl 1995, 19:91–94.
34. Shibagaki I, Tanaka H, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki
K: p53 mutation, murine double minute 2 amplification, and human
papillomavirus infection are frequently involved but not associated with
each other in esophageal squamous cell carcinoma. Clin Cancer Res 1995,
1:769–773.
35. Ito M, Barys L, O’Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S,
Choong PF, Dickinson I, Crowe P, Hemmings C, Desai J, Thomas DM, Lisztwan J:
Comprehensive mapping of p53 pathway alterations reveals an apparent role
for both SNP309 and MDM2 amplification in sarcomagenesis. Clin Cancer Res
2011, 17:416–426.
36. Forslund A, Zeng Z, Qin LX, Rosenberg S, Ndubuisi M, Pincas H, Gerald W,
Notterman DA, Barany F, Paty PB: MDM2 gene amplification is correlated
to tumor progression but not to the presence of SNP309 or TP53
mutational status in primary colorectal cancers. Mol Cancer Res 2008,
6:205–211.
37. Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D,
Pollok KE, Boothman DA, Mayo LD: TGF-beta1-induced expression of
human Mdm2 correlates with late-stage metastatic breast cancer.
J Clin Invest 2010, 120:290–302.
Lee et al. Cell Division 2014, 9:3 Page 14 of 14
http://www.celldiv.com/content/9/1/338. Chen X, Qiu J, Yang D, Lu J, Yan C, Zha X, Yin Y: MDM2 promotes invasion
and metastasis in invasive ductal breast carcinoma by inducing matrix
metalloproteinase-9. PLoS One 2013, 8:e78794.
39. Carroll PE, Okuda M, Horn HF, Biddinger P, Stambrook PJ, Gleich LL, Li YQ,
Tarapore P, Fukasawa K: Centrosome hyperamplification in human cancer:
chromosome instability induced by p53 mutation and/or Mdm2
overexpression. Oncogene 1999, 18:1935–1944.
40. Ganguli G, Wasylyk B: p53-independent functions of MDM2. Mol Cancer
Res 2003, 1:1027–1035.
41. Alt JR, Greiner TC, Cleveland JL, Eischen CM: Mdm2 haplo-insufficiency
profoundly inhibits Myc-induced lymphomagenesis. EMBO J 2003,
22:1442–1450.
42. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM,
Marechal V, Chen J, Brennan MF, Levine AJ: Molecular abnormalities of
mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 1994,
54:794–799.
43. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z,
Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C: Impact of alterations affecting
the p53 pathway in bladder cancer on clinical outcome, assessed by
conventional and array-based methods. Clin Cancer Res 2002, 8:171–179.
44. Meraldi P, Honda R, Nigg EA: Aurora-A overexpression reveals
tetraploidization as a major route to centrosome amplification in
p53-/- cells. EMBO J 2002, 21:483–492.
45. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S:
Tumour amplified kinase STK15/BTAK induces centrosome amplification,
aneuploidy and transformation. [see comments.]. Nat Genet 1998,
20:189–193.
46. Zeng X, Shaikh FY, Harrison MK, Adon AM, Trimboli AJ, Carroll KA, Sharma
N, Timmers C, Chodosh LA, Leone G, Saavedra HI: The Ras oncogene
signals centrosome amplification in mammary epithelial cells through
cyclin D1/Cdk4 and Nek2. Oncogene 2010, 29:5103–5112.
47. Kitajima TS, Sakuno T, Ishiguro K, Iemura S, Natsume T, Kawashima SA,
Watanabe Y: Shugoshin collaborates with protein phosphatase 2A to
protect cohesin. Nature 2006, 441:46–52.
48. Liu H, Rankin S, Yu H: Phosphorylation-enabled binding of SGO1-PP2A to
cohesin protects sororin and centromeric cohesion during mitosis.
Nat Cell Biol 2013, 15:40–49.
49. Kitajima TS, Kawashima SA, Watanabe Y: The conserved kinetochore
protein shugoshin protects centromeric cohesion during meiosis.
Nature 2004, 427:510–517.
50. Lee J, Kitajima TS, Tanno Y, Yoshida K, Morita T, Miyano T, Miyake M,
Watanabe Y: Unified mode of centromeric protection by shugoshin in
mammalian oocytes and somatic cells. Nat Cell Biol 2008, 10:42–52.
51. Tang Z, Sun Y, Harley SE, Zou H, Yu H: Human Bub1 protects centromeric
sister-chromatid cohesion through Shugoshin during mitosis. Proc Natl
Acad Sci U S A 2004, 101:18012–18017.
52. Takata H, Matsunaga S, Morimoto A, Ma N, Kurihara D, Ono-Maniwa R,
Nakagawa M, Azuma T, Uchiyama S, Fukui K: PHB2 protects
sister-chromatid cohesion in mitosis. Curr Biol 2007, 17:1356–1361.
53. Fu G, Ding X, Yuan K, Aikhionbare F, Yao J, Cai X, Jiang K, Yao X:
Phosphorylation of human Sgo1 by NEK2A is essential for chromosome
congression in mitosis. Cell Res 2007, 17:608–618.
54. Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jager D,
Chen YT, Mackay A, O’Hare MJ, Old LJ: Humoral immunity to human
breast cancer: antigen definition and quantitative analysis of mRNA
expression. Cancer Immun 2001, 1:4.
55. Wang Y, Liu L, Liu X, Zhang H, Liu J, Feng B, Shang Y, Zhou L, Wu K, Nie Y,
Zhang H, Fan D: Shugoshin1 enhances multidrug resistance of gastric
cancer cells by regulating MRP1, Bcl-2, and Bax genes. Tumour Biol 2013,
34:2205–2214.
56. Kahyo T, Iwaizumi M, Shinmura K, Matsuura S, Nakamura T, Watanabe Y,
Yamada H, Sugimura H: A novel tumor-derived SGOL1 variant causes
abnormal mitosis and unstable chromatid cohesion. Oncogene 2011,
30:4453–4463.
57. Yang J, Ikezoe T, Nishioka C, Yokoyama A: A novel treatment strategy
targeting shugoshin 1 in hematological malignancies. Leuk Res 2013,
37:76–82.
58. Iwaizumi M, Shinmura K, Mori H, Yamada H, Suzuki M, Kitayama Y, Igarashi
H, Nakamura T, Suzuki H, Watanabe Y, Hishida A, Ikuma M, Sugimura H:
Human Sgo1 downregulation leads to chromosomal instability in
colorectal cancer. Gut 2009, 58:249–260.59. Leber B, Maier B, Fuchs F, Chi J, Riffel P, Anderhub S, Wagner L, Ho AD,
Salisbury JL, Boutros M, Kramer A: Proteins required for centrosome
clustering in cancer cells. Sci Transl Med 2010, 2:33ra38.
60. Lan W, Cleveland DW: A chemical tool box defines mitotic and interphase
roles for Mps1 kinase. J Cell Biol 2010, 190:21–24.
61. Pike AN, Fisk HA: Centriole assembly and the role of Mps1: defensible or
dispensable? Cell Div 2011, 6:9.
62. Kasbek C, Yang CH, Fisk HA: Antizyme restrains centrosome amplification
by regulating the accumulation of Mps1 at centrosomes. Mol Biol Cell
2010, 21:3878–3889.
63. Kasbek C, Yang CH, Fisk HA: Mps1 as a link between centrosomes and
genomic instability. Environ Mol Mutagen 2009, 50:654–665.
64. Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E: High levels of the
Mps1 checkpoint protein are protective of aneuploidy in breast cancer
cells. Proc Natl Acad Sci U S A 2011, 108:5384–5389.
65. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E,
Marty-Prouvost B, De Koning L, Rigaill G, Dumont A, Gentien D, Barillot E,
Roman-Roman S, Depil S, Cruzalegui F, Pierré A, Tucker GC, Dubois T: TTK/
hMPS1 is an attractive therapeutic target for triple-negative breast
cancer. PLoS One 2013, 8:e63712.
66. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E,
Wilsbach K, Gabrielson E: Increased expression of mitotic checkpoint
genes in breast cancer cells with chromosomal instability. Clin Cancer Res
2006, 12:405–410.
doi:10.1186/1747-1028-9-3
Cite this article as: Lee et al.: Differential expression of centrosome
regulators in Her2+ breast cancer cells versus non-tumorigenic MCF10A
cells. Cell Division 2014 9:3.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
